Literature DB >> 25928075

Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.

George F Sawaya, Shalini Kulasingam, Thomas D Denberg, Amir Qaseem.   

Abstract

DESCRIPTION: The purpose of this best practice advice article is to describe the indications for screening for cervical cancer in asymptomatic, average-risk women aged 21 years or older.
METHODS: The evidence reviewed in this work is a distillation of relevant publications (including systematic reviews) used to support current guidelines. BEST PRACTICE ADVICE 1: Clinicians should not screen average-risk women younger than 21 years for cervical cancer. BEST PRACTICE ADVICE 2: Clinicians should start screening average-risk women for cervical cancer at age 21 years once every 3 years with cytology (cytologic tests without human papillomavirus [HPV] tests). BEST PRACTICE ADVICE 3: Clinicians should not screen average-risk women for cervical cancer with cytology more often than once every 3 years. BEST PRACTICE ADVICE 4: Clinicians may use a combination of cytology and HPV testing once every 5 years in average-risk women aged 30 years or older who prefer screening less often than every 3 years. BEST PRACTICE ADVICE 5: Clinicians should not perform HPV testing in average-risk women younger than 30 years. BEST PRACTICE ADVICE 6: Clinicians should stop screening average-risk women older than 65 years for cervical cancer if they have had 3 consecutive negative cytology results or 2 consecutive negative cytology plus HPV test results within 10 years, with the most recent test performed within 5 years. BEST PRACTICE ADVICE 7: Clinicians should not screen average-risk women of any age for cervical cancer if they have had a hysterectomy with removal of the cervix.

Entities:  

Mesh:

Year:  2015        PMID: 25928075     DOI: 10.7326/M14-2426

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  19 in total

Review 1.  Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

2.  Obstetrician-gynecologists' beliefs about performing less cervical cancer screening: the pendulum swings.

Authors:  Allison Schneider; Jillian T Henderson; Cynthia C Harper; Amy Hsu; Mona Saraiya; George F Sawaya
Journal:  Am J Obstet Gynecol       Date:  2015-07-14       Impact factor: 8.661

3.  Making Sense of Cervical Cancer Screening Guidelines and Recommendations.

Authors:  Michelle Davis; Sarah Feldman
Journal:  Curr Treat Options Oncol       Date:  2015-12

4.  Cost-effectiveness studies of HPV self-sampling: A systematic review.

Authors:  Colin Malone; Ruanne V Barnabas; Diana S M Buist; Jasmin A Tiro; Rachel L Winer
Journal:  Prev Med       Date:  2020-01-03       Impact factor: 4.018

5.  Why does cervical cancer occur in a state-of-the-art screening program?

Authors:  Philip E Castle; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Mark Schiffman
Journal:  Gynecol Oncol       Date:  2017-06-10       Impact factor: 5.482

Review 6.  Cervical Cancer Screening.

Authors:  George F Sawaya; Megan J Huchko
Journal:  Med Clin North Am       Date:  2017-04-21       Impact factor: 5.456

7.  Clinical Significance and Prognostic Value of Lactate Dehydrogenase Expression in Cervical Cancer.

Authors:  Yuping Ye; Min Chen; Xinyan Chen; Jingyu Xiao; Lin Liao; Faquan Lin
Journal:  Genet Test Mol Biomarkers       Date:  2022-03

8.  Multilevel Follow-up of Cancer Screening (mFOCUS): Protocol for a multilevel intervention to improve the follow-up of abnormal cancer screening test results.

Authors:  Jennifer S Haas; Steven J Atlas; Adam Wright; E John Orav; David G Aman; Erica S Breslau; Timothy E Burdick; Emily Carpenter; Frank Chang; Tin Dang; Courtney J Diamond; Sarah Feldman; Kimberly A Harris; Shoshana J Hort; Molly L Housman; Amrita Mecker; Constance D Lehman; Sanja Percac-Lima; Rebecca Smith; Amy J Wint; Jie Yang; Li Zhou; Anna N A Tosteson
Journal:  Contemp Clin Trials       Date:  2021-08-08       Impact factor: 2.261

Review 9.  HPV Update: Vaccination, Screening, and Associated Disease.

Authors:  Megan McNamara; Pelin Batur; Judith M E Walsh; Kay M Johnson
Journal:  J Gen Intern Med       Date:  2016-05-16       Impact factor: 5.128

Review 10.  Population-based screening for cancer: hope and hype.

Authors:  Yiwey Shieh; Martin Eklund; George F Sawaya; William C Black; Barnett S Kramer; Laura J Esserman
Journal:  Nat Rev Clin Oncol       Date:  2016-04-13       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.